logo
Share SHARE
FONT-SIZE Plus   Neg

Biogen Idec Sells BENLYSTA Royalty Rights To DRI Capital Managed Fund

Biogen Idec (BIIB) has sold to a DRI Capital managed fund its royalty and other rights pertaining to BENLYSTA to which Biogen Idec is entitled pursuant to a license deal with Human Genome Sciences Inc. (HGSI) and Glaxo Group Ltd. According to the agreement between Biogen Idec and DRI, Human Genome Sciences and Glaxo Group Ltd. would make royalty payments directly to DRI instead of to Biogen Idec. In turn, DRI would pay Biogen Idec a multiple of certain of the royalties received for the period covering October 2011 to September 2014.

Following that period, DRI would retain the royalty payments from BENLYSTA sales, with certain exceptions, including a one-time contingency payment that could be triggered if the cumulative royalties to DRI exceed an agreed amount. The initial payment by DRI to Biogen Idec, covering the royalty period from October 1, 2011 to March 30, 2012 is nearly $18.3 million and would be recognized into income as a gain in the third quarter.

BENLYSTA was approved by the US Food and Drug Administration in March 2011 and by the European Medicines Agency in July 2011 to treat systemic lupus erythematosus.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Tesla is planing to build full-service convenience stores at its charging stations, reports said, citing Tesla CTO JB Straubel. Earlier this week at the food tech conference FSTEC, Straubel mentioned the company's early plans to build some locations into rest stops to make customers' waiting more comfortable while they charge cars. Gatorade Co. agreed to pay $300,000 to settle a complaint with California over a mobile game that discouraged drinking water, the California attorney general's office said last week. The settlement terms also call for putting $120,000 toward the study or promotion of childhood and teenage nutrition and consumption of water. Consumer goods giant Unilever plc Monday said it has agreed to acquire Carver Korea, a Seoul-based maker of toners and moisturizers, for 2.27 billion euros from Bain Capital Private Equity and Goldman Sachs. The company expects the acquisition to help it to gain ground in the Korean beauty market, said to be the fourth largest skincare market in the world.
comments powered by Disqus
Follow RTT